Welcome to our dedicated page for Tvardi Therapeutics SEC filings (Ticker: TVRD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Tvardi Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Tvardi Therapeutics's regulatory disclosures and financial reporting.
Tvardi Therapeutics (TVRD) filed an amended S-1 that stresses the company is an early-stage clinical biotechnology company with no product revenue, an accumulated deficit of $92.2M and cash resources that management deems insufficient to fund operations for at least one year, creating substantial doubt about its ability to continue as a going concern. The filing describes lead programs TTI-101 (oral STAT3 inhibitor) and TTI-109, development plans in IPF and HCC, regulatory designations (orphan and Fast Track for TTI-101 in select indications), and trial timelines: a 12-week REVERT IPF Phase 2 study (38 randomized patients) with preliminary blinded data showing ~50% of participants near or above baseline FVC and an expected unblinded readout in Q4 2025, and a REVERT HCC Phase 1b/2 program with preliminary topline data expected in H1 2026. The company disclosed material financing instruments: Convertible Notes with
Slate Path Capital LP and David Greenspan report owning 704,118 shares (7.5%) of Tvardi Therapeutics (TVRD). The holdings are held by Slate Path Master Fund LP and SPB Master Fund LP and are reported as shared voting and dispositive power; neither reporting person claims sole voting or dispositive power. The percentage is calculated using 9,360,904 shares outstanding as of May 8, 2025. The filing states the shares were acquired in the ordinary course of business and were not acquired to change or influence control of the company.
Sporos Bioventures LLC reported direct beneficial ownership of 837,636 shares of Tvardi Therapeutics common stock, equal to 8.95% of the outstanding class. The filer discloses sole voting power and sole dispositive power over these shares, and reports no shared voting or dispositive arrangements.
This Schedule 13G statement records a material, reportable passive stake above the 5% threshold and provides investors with clear disclosure of concentrated ownership and voting control of a meaningful minority position in TVRD.
Schedule 13G/A (Amendment 1) discloses the current ownership of Tvardi Therapeutics, Inc. (TVRD) by Samuel D. Tweardy.
The filer reports 315,658 common shares, held via the Samuel David Tweardy 2020 Gift Trust, representing 3.4 % of the 9,373,433 shares outstanding as of 8 Aug 2025. He retains sole voting and dispositive power over the entire stake; no shared power is indicated.
Tweardy resigned as trustee of two related 2020 Gift Trusts—actions permitted under an existing 17 Dec 2024 lock-up agreement—so those trusts’ shares are no longer included in his beneficial ownership. Item 5 confirms the position is now 5 % or less of the class, qualifying the filing for passive Schedule 13G treatment. The certification states the shares were not acquired to influence control of the issuer.
Tvardi Therapeutics (TVRD) – Form 4 insider update: Director & 10% owner Samuel D. Tweardy disclosed that on 07 Jul 2025 he resigned as trustee of a family trust holding 315,658 common shares. Transaction code “J” indicates a transfer with no monetary consideration; stated price $0. Because the shares are now held by the trust without Tweardy’s control, his reported beneficial ownership fell from 315,658 shares to zero. The stock remains locked-up under the 17 Dec 2024 agreement, so the float is unchanged. No derivative positions or additional transactions were reported. While the filing does not reflect an open-market sale, it removes a sizable insider stake, potentially reducing insider–shareholder alignment. The document contains no operating or financial performance data.
FAQ
What is the current stock price of Tvardi Therapeutics (TVRD)?
What is the market cap of Tvardi Therapeutics (TVRD)?
